Gastrodin as a multi-target protective compound reverses learning memory deficits and AD-like pathology in APP/PS1 transgenic mice
Files
(Published version)
Date
2021
Authors
Zeng, Y.Q.
Gu, J.H.
Chen, L.
Zhang, T.T.
Zhou, X.F.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Functional Foods, 2021; 77(article no. 104324):1-8
Statement of Responsibility
Conference Name
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Evidence suggests that people can benefit from consumption of diets rich in plant phenolics because they can attenuate AD symptoms. The phenolic glucoside gastrodin is the main bioactive compound of Rhizoma Gastrodiae and is widely used for treating various neurological disorders. In this study, we assess whether long term oral administration of gastrodin can improve cognitive impairment and AD-like pathology. Our results showed that chronic gastrodin administration inhibits aggregation and disaggregate oligomeric and fibrillar species of A beta 42, prevents A beta 42 induced neurotoxicity in cell SH-SY5Y, decreases the levels of A beta plaques and hyperphosphorylated tau, alleviates activation of glial cells and proinflammatory cytokines, attenuates oxidative stress in the APP/PS1 transgenic mice. The mechanisms underlying can be attributed to the inhibition levels of enzymes of A beta and prevention GSK3 beta activity. Our results suggest that gastrodin might be a potential agent for the treatment of AD.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supplementary information, https://doi.org/10.1016/j.jff.2020.104324
Access Status
Rights
Copyright 2020 Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)